After obtaining data indicating the presence of a neutrophil attractant protein-1 (NAP-1)-IgG complex in normal human serum, we developed sandwich ELISAs that could quantify NAP-1 and NAP-1-IgG in mixtures of the two moieties. The ELISA for free NAP-1 used a monoclonal capture antibody that did not bind NAP-1-IgG. The ELISA for NAP-1-IgG was based on omission of the anti-NAP-1 detection antibody (required for the free NAP-1 ELISA) and on interaction of phosphatase-conjugated anti-human IgG with the human NAP-1-IgG complex. Gel filtration of immunoaffinity-purified NAP-1-IgG showed that the bulk of the complex comprised a single IgG. Binding between NAP-1 and antibody is strong, since 8 M urea at neutral or alkaline pH did not release NAP-1. However, at pH 2.0 in 9 M urea 15% of the total NAP-1 could be dissociated from the complex. NAP-1-IgG was detected in 18 of 26 sera from normal humans. The mean serum concentration was 58 ng of IgG-bound NAP-1 /ml, with an SEM of 16 and a range from undetectable to 247 ng/ml. NAP-1-IgG concentrations in paired sera drawn at a 1-mo interval were remarkably constant. Using an ELISA for free NAP-1 with a detection limit of 200 pg/ml, we found no free NAP-1 in the 26 sera. Free anti-NAP-1-IgG autoantibody was found in 9 of 26 sera by direct ELISA. IgG anti-NAP-1 of all nine sera was polyclonal, comprising both kappa and lambda isotypes; predominant subclasses were IgG2 and IgG3. NAP-1-IgG did not compete with 125I-NAP-1 for binding to neutrophils, which suggests that IgG anti-NAP-1 is a molecular trap that prevents binding of NAP-1 to neutrophils after it diffuses from production sites into the circulation. (J. Clin. Invest. 1992. 90:471-481.) Key words:
protein, which was recently isolated, sequenced, and cloned (for review see reference 2). NAP-1 is synthesized and secreted by LPS-stimulated monocytes or macrophages. It is also secreted by numerous other cells, including epithelial and endothelial cells, lymphocytes, fibroblasts, and keratinocytes. The list of NAP-I production stimuli, which includes LPS, zymosan, IL-1, TNF, and rubella, suggests that NAP-I is a host defense cytokine, which is secreted as part ofthe response to noxious or infectious agents (2) . This view is supported by the sequence similarity of NAP-1 to a family of small host defense proteins (3) and by detection of NAP-I at inflammatory sites characterized by neutrophil infiltration. The latter include extraction ofNAP-I from human psoriatic scales (4), purification of NAP-I from zymosan-induced rabbit peritoneal exudate (5) , and detection of NAP-I by immunoassay in synovial fluid ofpatients with arthritis (6) and in bronchoalveolar lavage fluid of cystic fibrosis patients infected with Pseudomonas (7).
Since NAP-I is resistant to proteolytic digestion (8) , the intact molecule may diffuse from its production source at sites of infectionkor tissue injury into the circulation. We therefore used a recently developed ELISA for NAP-1 (9) to determine if this chemoattractant was detectable in sera from healthy humans and patients with inflammatory joint effusions. Exploration ofpreliminary results led to the work reported here, which shows that serum of normal subjects contains a NAP-i -IgG complex and also free anti-NAP-I antibody. The data suggest that under physiological conditions NAP-I is released at tissue sites, where neutrophils can respond to the NAP-I concentration gradient. NAP-I subsequently diffuses into the blood where NAP-I is prevented from binding to its target neutrophils by forming a complex with IgG anti-NAP-1.
Methods
Serum samples. Blood samples from 26 healthy volunteers were drawn into iced syringes, and cells were removed immediately by centrifugation at 3,000 rpm, 40C (centrifuge model TJ-6; Beckman Instruments, Inc., Palo Alto, CA). Supernatants were transferred into glass tubes and incubated at 37°C for -30 min to allow clotting. After the clot was removed, serum samples were filtered through 0.45-am pore-size Centrex filter units. Aliquots were stored at -800C until assay. Serum samples from 12 ofthe 26 donors were obtained twice, 1 mo apart, and paired sera were assayed for NAP-l-IgG and free NAP-1 on the same day.
Sandwich ELISAsfor NAP-I. Mouse monoclonal TY anti-NAP-I and rabbit polyclonal anti-NAP-l IgG antibodies (9) , monoclonal 8C4, 14E4, and 52E8 anti-NAP-l antibodies (10) , monoclonal IC anti-NAP-l (1 1, 12) , and other reagents required for the ELISA (9) have been previously described. 10 ,000 rpm for 15 min and 0.1 % NaN3 was added as a preservative. The preparation was kept at 4°C.
The initial ELISA steps (coating with monoclonal capture antibody, blocking, addition of human serum for assay) were identical to those described above. Wells were then incubated with biotinylated rabbit anti-NAP-1, followed by two 1 5-min room temperature equilibrations. The first was with avidin (Vector Laboratories, Inc., Burlingame, CA) at a concentration of 10 ,g/ml in 0.1 M NaHCO3; the second was with biotinylated alkaline phosphatase (Vector Laboratories, Inc.) at a concentration of 0.2 U/ml in TBS + 0.05% Tween-20). Finally, after six washes with TBS without Tween-20, the ELISA Amplification System was used to develop the reaction, and absorbance at 490 nm was recorded.
Direct ELISA. We examined specificity of monoclonal and rabbit polyclonal anti-NAP-1 antibodies by this method. Purified antigens (NAP-1, NAP-2, CTAP-III) were dissolved in coating buffer and bound to ELISA wells by overnight equilibration at 4°C. Vacant sites were blocked with 0.2% BSA diluted in coating buffer. Rabbit or mouse anti-NAP-I in washing buffer at a concentration of 5 4g/ml was added and incubated for 90 min at 37°C. Bound rabbit or mouse anti-NAP-l was detected with alkaline phosphatase-conjugated antibody to mouse or rabbit IgG.
Purification ofHSA for blocking ELISA plates. For purification of HSA (14) , 100 ml of serum was heated at 56°C for 30 min. Ammonium sulfate was added slowly to continuously stirred serum at room temperature until the concentration was 2 M. After removal ofprecipitate by centrifugation, pH of the supernatant was adjusted to 4.0 with 0.3 N HCI. Precipitated protein was separated by centrifugation, suspended in potassium phosphate buffer (0.1 M, pH 7.0), and dissolved by dialysis overnight against several changes of 0.15 M NaCl, 0.01 M potassium phosphate (pH 7.0). The albumin solution was passed through a Protein-G Sepharose column five times to remove residual IgG. The purified HSA did not react with alkaline phosphatase-labeled goat anti-human IgG in a direct ELISA and was effective as a blocking protein to prevent binding of subsequent reagents to the ELISA wells.
ELISA forfree anti-NAP-I antibody in normal human sera. Human recombinant NAP-1 at a concentration of 2 yg/ml (200 ng/well) in coating buffer was added to ELISA wells and equilibrated overnight at 40C. Unoccupied sites on the plastic were blocked by 0.3 ml/well of purified HSA (purified as described above) diluted in coating buffer to a concentration of 1 mg/ml. Control wells to which NAP-I had not been added were also blocked with HSA. Blocking with IgG-free HSA resulted in a lower background than with BSA and was critical for detection and quantitative estimation of anti-NAP-1. After one wash, serum samples at 1:2 dilution in washing buffer were added to triplicate wells and incubated 2 h at 370C. Bound IgG was detected by alkaline phosphatase-conjugated goat anti-human IgG (Jackson ImmunoResearch Labs, Inc., West Grove, PA). The reaction was developed with p-nitrophenyl phosphate disodium (Sigma 104 Phosphatase Substrate Tablet; Sigma Chemical Co.), and absorbance was measured at 405 nm with an automated ELISA reader. For each serum sample, the difference between NAP-I well and control well A405 was attributable to free anti-NAP-1. Control reactions ofanti-human IgG with HSA and antihuman IgG with NAP-I were negative.
After identifying serum samples with detectable free anti-NAP-I antibody, we repeated the assay to make quantitative estimates ofanti- Additional assays were performed to determine the IgG subclass and the light chain isotype of IgG anti-NAP-I autoantibody in sera of normal human subjects. Serum IgG from these subjects was purified on Protein-G columns and adjusted to a concentration of I mg/ml. ELISA plates, except for control wells, were coated with NAP-I and blocked with HSA as in the above procedure. We then added I mg/ml purified IgG from the series of human subjects or I mg/ml normal human IgG (ChromoPure; Jackson ImmunoResearch Labs., Inc.) to triplicate wells. Light chain isotype was probed by addition of mouse monoclonal anti-human kappa-and lambda-light chain antibodies (Boehringer Mannheim GmbH, Mannheim, FRG), followed by alkaline phosphatase-labeled goat anti-mouse IgG (Sigma Chemical Co.). IgG subclasses were determined with subclass-specific mouse mAbs (HP6069 anti-IgGI, HP6002 anti-IgG2, HP6047 anti-IgG3, and HP6023 anti-IgG4) produced by Hybridoma Reagent Laboratory (Kingsville, MD). Absorbance values due to HSA-IgG interaction were subtracted from those of the NAP-I-containing wells. No crossreactivity between bound human IgG and alkaline phosphatase-conjugated anti-mouse IgG was detected.
LPS stimulation ofhuman blood mononuclear leukocytes. Donors S.I. and E.L. (one with undetectable and the other with high serum NAP-I-IgG) were selected to determine if there was a quantitative difference between NAP-I production by their LPS-stimulated PBMCs. 50 ml of blood from each donor was drawn into sterile syringes containing 500 U heparin sodium (The Upjohn Company, Kalamazoo, MI). After Ficoll-Hypaque separation and three washing steps, cells were resuspended in RPMI 1640 (Advanced Biotechnologies, Inc., Silver Spring, MD) containing 5% heat-inactivated FCS (Hyclone Laboratories Inc., Logan, UT), 2 mM L-glutamine, 50 ,g/ml gentamycin sulfate, and 10 ,g/ml Escherichia coli LPS 055:B5 (Difco, Detroit, MI). Cells were incubated at a concentration of 5 x 106 cells/ml in a Costar 24-well tissue culture plate (Costar Corp., Cambridge, MA) for 36 h at 37°C. Cell-free supernatants were obtained by centrifugation and filtration through 0.45-Mm pore-size Centrex filter units. Cells for the control were incubated without LPS; after incubation, LPS was added to the cell-free supernatants at a concentration of 10 gg/ml. NAP-I concentration was determined by sandwich ELISA.
Affinity chromatography of human serum on a monoclonal anti-NAP-i column. 12 mg of purified monoclonal anti-NAP-I IgG was coupled to 3.5 ml packed volume of CNBr-activated Sepharose 4B (Pharmacia-LKB, Piscataway, NJ). After a preliminary wash of the column with 0.1 M glycine-HCI buffer (pH 2.5) and equilibration with PBS, 25 ml or 8.5 ml of filtered human serum was passed through the column at a flow rate of0.5 ml/mmin. After the column was washed with 50 ml 2 M NaCi, bound proteins were eluted with 0.1 M glycine-HCl buffer (pH 2.5). I-ml fractions were collected into Minisorp tubes (Nunc, Copenhagen, Denmark) containing 0.1 ml of0.5 M potassium phosphate buffer (pH 7.8). Absorbance was measured at 280 nm. A pool of A280 positive fractions was dialyzed overnight at 40C against TBS or PBS, depending on requirements of the subsequent assay. A column of mouse monoclonal IgG directed against a protein unrelated to NAP-i and an uncoupled CNBr-Sepharose 4B column (blocked with 0.1 M Tris-HCI buffer, pH 8.0) of the same size were used for controls.
HPLC gel filtration of anti-NAP-i column eluate and untreated human serum. HPLC gel filtration of I00-,d samples was performed at room temperature on a 7.5 x 600 mm TSK-2000 column (Toyo Soda, Tokyo, Japan), equilibrated with Dulbecco's PBS (pH 7.4). i-ml fractions were collected at a flow rate of 1 ml/min, and A280 was recorded at an absorbance range of 0.16. The column was calibrated with catalase, ribonuclease (both from Pharmacia-LKB), and ChromoPure human IgG. Fractions were assayed in the sandwich ELISA with both biotinylated rabbit anti-NAP-I and enzyme-linked anti-human IgG as detecting antibodies.
SDS-PAGE of anti-NAP-i column eluate. Electrophoresis was carried out on a vertical slab gel of7.5% acrylamide with a Tris-glycine buffer system. Anti-NAP-I column eluate and control mouse IgG were mixed with equal volumes ofdouble-strength sample buffer (20% glycerol, 4% SDS, without 2-mercaptoethanol), boiled, and applied to the gel in amounts of 5, 10, and 20 ug/ lane. After a 2-h run at 16 mA, the gel was removed and stained with Coomassie blue. NAP-I and NAP-l-IgG (Table III) . Since these anti-NAP-I antibodies did not react with CTAP-III, we conclude that they captured the IgG complex via NAP-I in the complex. Assays to distinguish NAP-I and NAP-i-IgG in mixtures. Monoclonal IC anti-NAP-i is unique among the antibodies listed in Table III : it was the best capture antibody for free NAP-I but did not function as capture antibody for NAP-1-IgG. Thus, it appears to interact with a NAP-I epitope that is blocked in NAP-I-IgG, as indicated in Figure 1 C. By using I C monoclonal anti-NAP-I as capture antibody in a sandwich ELISA, we could quantify free NAP-I in mixtures of NAP-I and NAP-I-IgG. As shown in Fig. 2 , assay values for fiee NAP-1 were not increased by the presence of NAP-1-IgG. The converse is illustrated in Fig. 3 , which shows that by omission of rabbit anti-NAP-I detection antibody, NAP-I-IgG can be quantified in the presence of free NAP-1.
Since rabbit anti-NAP-I played no role in the detection of NAP-I-IgG (Table I) , it was possible that the free NAP-I epitope (or epitopes) with which rabbit anti-NAP-I reacted was blocked in the IgG complex. We confirmed this by a NAP-I sandwich ELISA that used biotinylated rabbit anti-NAP-I as the detecting antibody and thus avoided the use of an enzymeconjugated anti-rabbit IgG. When NAP-l-IgG was tested in this assay, no NAP-I reactivity was found, indicating that biotinylated rabbit anti-NAP-l did not bind to the NAP-l-IgG complex (Fig. 4) . The legend of Fig. 1 summarizes our 
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IgG in fractions eluted from the TSK-2000 column was determined by sandwich ELISA. Fig. 5 shows that the bulk of the NAP-l-IgG coeluted with the major A280 peak, which is in the location of the IgG marker. Therefore, the NAP-l-IgG complex comprises only one IgG plus one NAP-1 molecule (or at most two NAP-Is per divalent IgG). SDS-PAGE ofthe starting material applied to the TSK-2000 column showed that almost all the protein is IgG (Fig. 5, inset) . However, NAP-l-IgG comprises only a small percentage of the total IgG, which is evident from the y-axis scales in Fig. 5 (A280 values reflect iugs IgG/ml, in contrast to ng/ml of complex). This is due to nonspecific binding ofserum IgG to Sepharose columns (including Sepharose alone, Sepharose coupled to mouse IgG, or Sepharose-IgG-anti-NAP-I ), which is then eluted by pH 2.7 glycine buffer. We attempted to dissociate the NAP-I-IgG complex by gel filtration on Sephadex G-100 in 8 or 9 M urea at pH 7.4, 2.0, and 10.0. Fig. 6 shows that at neutral pH we failed to dissociate the complex, since NAP-l ELISA reactivity was eluted at the IgG marker and not in the location for free NAP-1. However, we altered the complex sufficiently to expose the two blocked epitopes outlined in Fig. 1 C. In contrast to the undenatured complex, urea-treated NAP-1 -IgG reacted in a sandwich ELISA that uses biotinylated rabbit anti-NAP-1 as detecting antibody; and it was captured by monoclonal IC (Fig. 6, closed  circles) , which is incapable of binding the native NAP-l-IgG complex (Table III , last row; Fig. 1 C) . Although similar results were obtained at pH 10.0, -15% of NAP-I in the NAPl-IgG complex was completely released in 9 M urea at pH 2.0 (Fig. 7) . with native NAP-l-IgG (Table III, Human serum concentrations of NAP-J-IgG: differences between subjects, but constant values over timefor individual subjects. Fig. 9 shows serum concentrations of NAP-1 -IgG for 26 normal human subjects. There is a wide range ofconcentrations and no correlation with age or sex. The mean for the group is 58 ng ofcomplex NAP-I /ml serum, with a SEM of 16 and a range from undetectable to 247 ng/ml. NAP-l-IgG was measured in paired sera obtained at a 1-mo interval from 12 normal subjects. Serum was prepared as described in Methods and stored in aliquots at -80'C. Paired sera from each subject were assayed on the same day. For all 12 subjects there was no detectable alteration in the serum concentration ofNAP-l-IgG over the 1-mo interval. This remarkable finding applied equally to the three subjects with undetectable NAP-1-IgG, to subjects with intermediate values, and to the person with 247 ng/ml.
The undetectable levels of NAP-l-IgG in serum of 8 of the 26 subjects suggested the possibility of a NAP-1 isoform that did not react with the monoclonal capture antibody. Therefore we stimulated the PBMCs of two subjects, one with high, and the other with undetectable, serum NAP-l-IgG. The sandwich ELISA detected comparable amounts ofNAP-1 in both culture fluids. This showed that the absence ofdetectable serum NAP- I -IgG in one of the two individuals was not due to inability of the monoclonal capture antibody to interact with her NAP-i. Survey ofnormal human seraforfree NAP-I and anti-NAP-1. The presence of NAP-l-IgG in serum suggested that either free antigen or antibody might also be detectable. We surveyed the 26 sera with a sandwich ELISA for free NAP-1, using IC monoclonal anti-NAP-I as capture antibody since it does not bind NAP-I-IgG (Table III and Fig. 1 C) . Using this assay, which has a detection limit of 200 pg/ml, we found no free NAP-I in sera from the 26 normal subjects. In an attempt to concentrate possibly low concentrations of NAP-i in human serum, we applied 5-ml aliquots oftwo human sera to monoclonal TY anti-NAP-I Sepharose columns. In the glycine buffer eluate of a donor with undetectable serum NAP-I-IgG, we detected 700 pg free NAP-I /ml of eluate. This represents a serum concentration (assuming no losses) of 140 pg/mi since the column eluate was fivefold concentrated relative to the starting serum volume. No free NAP-I was found in the glycine eluate of the other serum, which had a NAP-I-IgG concentration of 247 ng/ml.
In contrast to the absence of free NAP-1, we detected free anti-NAP-I antibody in 9 of the 26 sera by direct ELISA with recombinant NAP-I adsorbed to the ELISA wells and IgG-depleted human albumin as the blocking agent (see Methods and Table IV ). We also detected free anti-NAP-I antibody in highly purified commercially available human IgG (ChromoPure IgG). One of the nine sera was also tested for capacity to immunoprecipitate metabolically labeled NAP-1; the resulting radioactive band was comparable in location to that obtained with rabbit anti-NAP-I (data not shown).
The light chain isotype and IgG subclass offree anti-NAP-I antibody were determined in Protein-G-purified IgG samples from eight donors and also in commercial human IgG (see Methods). Both kappa and lambda light chains were detected in all samples, indicating that anti-NAP-I autoantibody is polyclonal (data not shown). A405 values obtained with IgG subclass-specific antibodies are shown in Fig. 10 . IgG2 and IgG3 were the predominant subclasses ofanti-NAP-I autoantibodies in the IgG of all donors as well as in commercial IgG. The low level of IgGl in the anti-NAP-I fraction of human IgG is remarkable, in view of the fact that it comprises -65% of the total IgG in normal human serum.
Discussion
Evidence relevant to our hypothesis that NAP-1 ELISA reactivity in human serum is due to NAP-l-IgG is as follows: (a) NAP-I sandwich ELISA values for serum were the same, with or without the addition of rabbit IgG anti-NAP-l detection antibody (Table I) . This led to the schema outlined in Fig. 1 B. Fig. 1 C) . This suggests that partial unfolding occurred, exposing a NAP-1 epitope that is buried in the native complex. Furthermore, 9
M urea at pH 2.0 caused 15% of the total NAP-I in the complex to dissociate, and it eluted from a gel filtration column in a location corresponding to free NAP-1. Using a sandwich ELISA with a detection limit of 200 pg/ ml, we found no free NAP-I in our group of 26 normal human sera. It was detected in immunoaffinity column eluates from one of two sera that were concentrated fivefold relative to serum concentration. The serum of this individual contained neither detectable NAP-l-IgG nor detectable free anti-NAP-I antibody. Our results for free NAP-I in serum are consistent with data in the literature. For example, Martich et al. ( II ) detected NAP-I concentrations of 26-46 pg/ml in 4 of 25 normal subjects, levels that are below the detection limit of our assay. Control human sera (number not specified) for experiments reported by Davenport et al. ( 19) had NAP-I concentrations of -100 pg/ml. The data of Martich et al. ( 11) are for free NAP-1, since the capture antibody in the sandwich ELISA was monoclonal IC anti-NAP-I, which does not react with NAP-I -IgG. Thus, the concentration of free NAP-I in normal human serum is undetectable or in the low picogram range. This is in contrast to NAP-I-IgG, which is in the nanogram range (mean of 58 ng/ml, excluding the IgG weight).
Investigation ofthe different specificities and cross-reactivities ofmonoclonal anti-NAP-I antibodies have led us to postulate a surprisingly large number of different epitopes for this relatively small protein (Fig. 1, legend) . In this context, what is the meaning of undetectable NAP-l-IgG in eight of the surveyed sera? Could those sera have a NAP-I immune complex, the IgG of which blocks the epitopes required for interaction with capture antibody? To evaluate this possibility, we assayed the negative sera in two additional ELISAs for NAP-I-IgG, using monoclonals 14E4 and 52E8 as capture antibodies, which bind to different NAP-I epitopes. The negative sera also had undetectable NAP-l-IgG in these assays (data not shown), which makes the blocked epitope hypothesis unlikely. It is probable that the eight sera with undetectable NAP-I -IgG contain the complex at a concentration that is at the lower end of a broad distribution curve for normal humans.
The gel filtration data in Fig. 5 show that the bulk of NAP-I-IgG, as determined by sandwich ELISA, eluted with the IgG marker. Thus, the immune complex comprises one IgG and one or at most two NAP-I molecules per divalent IgG. The small shoulder at the beginning ofthe NAP-I-IgG ELISA peak is probably due to experimentally induced aggregation. However, in view ofthe evidence for several epitopes on the NAP-I molecule, the shoulder could be a complex with two IgGs. Ishizaka et al. (20) showed that two IgGs in an immune complex were the minimum number required for eliciting skin reactivity or complement activation. Since the bulk of the NAP-1-IgG immune complex comprises one IgG, it should not be pathogenic, a view supported by its presence in healthy human subjects.
The presence of NAP-I -IgG in normal human serum suggests the following hypothesis. Homeostatic responses in normal individuals include tissue cell secretion of NAP-1, which subsequently diffuses into the circulating blood. Since binding to blood neutrophils would inhibit the neutrophil response to a chemotactic gradient, prevention of binding by a NAP-I trapping mechanism might exist, antibody, a2-macroglobulin, or other cells with NAP-I receptors being possible examples. This role is fulfilled by NAP-I-IgG, which does not compete with 1251-NAP-1 for binding to neutrophil NAP-I receptors (Fig. 8) .
The concentration ofNAP-I -IgG in a group ofnormal human sera is in the nanogram range (< 1-247 ng/ml, Fig. 9 ). The concentration of free NAP-I in serum of normal humans is in the picogram range (below a detection limit of 20-46 pg/ml (I I )]. The concentration of serum anti-NAP-I is 10-100 ng/ml (Table IV) . If we assume that the low concentration of free serum NAP-I reflects equilibrium between antigen, antibody, and the complex, the Kd of anti-NAP-i must be <-10" M. Thus, under normal conditions, this high affinity antibody is capable oflimiting free NAP-I concentration in the serum to a reported level (the order of 10-12 M) that is considerably below the optimal neutrophil stimulatory concentration of 10-8 M. In response to intravenous LPS, a powerful stimulus for NAP-I secretion, the serum concentration of free NAP-1 rose to a peak of 500-900 pg/ml (-10-10 M) within 3 h ( 11 ). It would be of interest to know if serum anti-NAP-I in these subjects was saturated by a flood of secreted NAP-1, resulting in elevated NAP-l-IgG as well as detectable free NAP-1.
Cells in the circulating blood other than neutrophils are capable of binding NAP-1. We reported that human monocytes bind NAP-1, despite lack ofa chemotactic response ( 16) . In an interesting publication by Darbonne et al. (21) , it was shown that human erythrocytes were capable of binding 12511 NAP-I with a Kd of 5 X 10-1 M. The authors did not report attempts to detect a preexisting NAP-l-erythrocyte complex in blood. Such a complex appears to be unlikely, given a Kd of 5 x IO-9 M and a serum free NAP-I concentration on the order of 10-12 M. Thus, the in vivo significance of the NAP-I-binding capacity of erythrocytes remains to be determined.
If serum NAP-I-IgG reflects a trapping mechanism to maintain free chemoattractant at low levels, the same might apply to other chemoattractants. Therefore, we looked for an IgG complex with monocyte chemoattractant protein-1 (MCP-1), a recently described attractant with 24% sequence similarity to NAP-1 (22, 23) . MCP-l-IgG was found in all 26 sera from the NAP-l-IgG study group. In relation to the possibility of an IgG trap for small protein attractants in general, it will be pertinent to develop assays for a serum C5a-IgG complex.
It is of interest that we found free anti-NAP-I antibody in 9 of 26 sera by ELISA. Antibody to IL-I and TNF has been found in the serum of normal subjects (24) . In a recent review, Avrameas (25) lists antibodies to other proteins found in normal serum, including interferons and TNF. Does production of antibody to these proteins reflect abrogation of tolerance or is tolerance never developed?
IgG-anti-NAP-1 comprised both kappa and lambda light chain isotypes in all nine normal subjects with detectable free anti-NAP-1, which shows that these auto-antibodies are polyclonal. The relatively high ELISA A405 values for IgG2 and IgG3 anti-NAP-I subclasses ofeight normal subjects were similar to the A405 distribution pattern found for anti-NAP-I subclasses in commercial IgG (Fig. 10) . This suggests that the observed distribution for the eight normal subjects reflects that of the general population. Although we do not know how closely the A405 values of Fig. 10 reflect subclass concentrations, the data suggest that the relative concentration of IgGl anti-NAP-I is considerably less than the 65% IgG 1 reported for total serum IgG. The significance of this apparent predominance of IgG2 and IgG3 among anti-NAP-I antibodies is not known. It will be of interest to determine the subclass of other nonpathogenic autoantibodies that have a possible role in homeostasis. Subclass heterogeneity ofthe autoantibody may also be associated with differences in affinity, which could account for incomplete dissociation of the NAP-I-IgG complex at pH 2.0 in 9 M urea.
Although the concentration of NAP-I-IgG in normal human serum covered a wide range, the concentration in any individual measured at a i-mo interval was remarkably constant. This stability may relate to mechanisms for removal of the complex. As noted above, NAP-1-IgG will not be ingested via Fc receptors of phagocytic cells, since complexes with a single IgG fail to activate pathways of Fc transduction. The relatively stable serum level of NAP-1-IgG in individual sera can be accounted for if we assume that NAP-l-IgG is eliminated by a first-order reaction with a 23-d half-life, similar to that offree IgG (26) . In the steady state, production (and degradation) of the complex would be -3% of the total per day. Therefore, a threefold increase in the rate of NAP-1 complex formation for 1 d would make a change of only 9% in the total concentration of NAP-I-IgG. In other words, a relatively long half-life minimizes changes in NAP-l-IgG concentration secondary to fluctuations in NAP-i production.
Since we have developed assays that can quantify NAP-I and NAP-1-IgG independently of one another, it will now be practical to look for alterations in disease. In fact, the studies described in this paper were stimulated by the finding of NAP-1 ELISA reactivity in synovial fluids of patients with arthritis. We then asked whether the presumed NAP-I was generated by synovial tissue or reflected serum protein concentrations characteristic of an exudate. This led to detection ofNAP-I ELISA reactivity in normal serum and to the studies described in this paper. Using assays for free NAP-I and the complex, we found NAP-l-IgG concentrations of4-42 ng/ml, but no free NAP-I (detection limit 1 ng/ml), in 14 of 16 inflammatory joint fluids (unpublished data). Based on a radioimmunoassay with a rabbit anti-NAP-I antibody, Brennan et al. (6) reported NAP-I concentrations in the range of 1-9 ng/ml in joint fluids from patients with rheumatoid and non-rheumatoid arthritis. Did that study detect free NAP-1, NAP-l-IgG, or both? If the epitopes with which their rabbit anti-NAP-I reacts are blocked by the IgG of NAP-I-IgG, the radioimmunoassay might have detected only free NAP-1. Evaluation of the specificity of the radioimmunoassay could now be made by testing pure NAP-I and serum-derived NAP-I-IgG.
Measurement of serum NAP-I or NAP-l-IgG might be diagnostically useful in certain clinical conditions. An example is pulmonary fibrosis, the management of which depends in part on knowing when intermittent episodes of clinically silent pulmonary inflammation occur. Diagnostic bronchoalveolar lavage has been advocated. A less invasive approach would be preferable. If serum NAP-I or NAP-1-IgG increased during inflammatory episodes, this finding could be used as an indication for therapy. Detection of serum neutrophil chemotactic factor in asthma is an example of a locally elaborated cytokine recoverable in the circulation (27) ; and a rising serum NAP-I has been found in experimentally induced endotoxemia or sepsis (28) .
